Education
About Us
Working with TipRanks
Follow Us
Basilea Pharmaceutica (CH:BSLN)
:BSLN
BSLN Stock Chart & Stats
CHF54.10
CHF0.45(0.96%)
At close: 4:00 PM EST
CHF54.10
CHF0.45(0.96%)
Day’s Range― - ―
52-Week RangeCHF37.50 - CHF59.70
Previous CloseN/A
Volume30.09K
Average Volume (3M)41.01K
Market Cap
CHF674.83M
Enterprise ValueCHF614.24M
Total Cash (Recent Filing)CHF128.37M
Total Debt (Recent Filing)CHF96.79M
Price to Earnings (P/E)9.0
Beta1.11
Next Earnings
Feb 17, 2026EPS Estimate
1.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.26
Shares Outstanding13,318,976
10 Day Avg. Volume32,790
30 Day Avg. Volume41,007
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)6.17
Price to Sales (P/S)2.40
P/FCF Ratio6.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF87.00Price Target Upside60.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Global Commercial FootprintAnalyst highlights that Cresemba's broad global approval and marketed presence support continued revenue growth and can trigger sales-based milestone payments to strengthen cash flow.
Pipeline SuccessionAnalyst points out that fosmanogepix as a potential successor to Cresemba could secure regulatory approvals before Cresemba's market wanes, helping to mitigate a future revenue cliff.
Strategic PartnershipAnalyst notes that the partnership with Phare Bio uses artificial intelligence to accelerate antibiotic discovery, which could expand the company's pipeline and create new long-term growth opportunities.
Bears Say
Clinical Development RiskAnalyst cautions that clinical setbacks with fosmanogepix could delay or prevent approval, jeopardizing expected pipeline-driven growth.
Partner Execution RiskAnalyst warns that reliance on external partners to commercialize isavuconazole and ceftobiprole creates execution risk that could limit revenue potential if partners underperform.
Revenue Visibility RiskAnalyst warns that limited control over partner-led assets may produce revenue uncertainty and reduce visibility into future cash flows from key products.
Basilea Pharmaceutica News
BSLN FAQ
What was Basilea Pharmaceutica’s price range in the past 12 months?
Basilea Pharmaceutica lowest stock price was CHF37.50 and its highest was CHF59.70 in the past 12 months.
What is Basilea Pharmaceutica’s market cap?
Basilea Pharmaceutica’s market cap is CHF674.83M.
When is Basilea Pharmaceutica’s upcoming earnings report date?
Basilea Pharmaceutica’s upcoming earnings report date is Feb 17, 2026 which is in 33 days.
How were Basilea Pharmaceutica’s earnings last quarter?
Basilea Pharmaceutica released its earnings results on Aug 19, 2025. The company reported CHF1.26 earnings per share for the quarter, missing the consensus estimate of CHF2.03 by -CHF0.77.
Is Basilea Pharmaceutica overvalued?
According to Wall Street analysts Basilea Pharmaceutica’s price is currently Undervalued.
Does Basilea Pharmaceutica pay dividends?
Basilea Pharmaceutica pays a Notavailable dividend of CHF5 which represents an annual dividend yield of N/A. See more information on Basilea Pharmaceutica dividends here
What is Basilea Pharmaceutica’s EPS estimate?
Basilea Pharmaceutica’s EPS estimate is 1.73.
How many shares outstanding does Basilea Pharmaceutica have?
Basilea Pharmaceutica has 13,318,976 shares outstanding.
What happened to Basilea Pharmaceutica’s price movement after its last earnings report?
Basilea Pharmaceutica reported an EPS of CHF1.26 in its last earnings report, missing expectations of CHF2.03. Following the earnings report the stock price went down -7.561%.
Which hedge fund is a major shareholder of Basilea Pharmaceutica?
Currently, no hedge funds are holding shares in CH:BSLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
BSLN Stock 12 Month Forecast
Average Price Target
CHF87.00
▲(60.81% Upside)
Technical Analysis
Molecular Partners AG
―
Idorsia Ltd
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---